Teleflex Incorporated (TFX) Earnings Call Transcript & Summary
July 28, 2022
Earnings Call Speaker Segments
Lawrence Keusch
executiveHello, everybody, and thanks for joining Teleflex Incorporated's Q2 2022 earnings conference call. You can find the slides and press release for this session on our site, teleflex.com. Just a note that this call is being webcast, and there will be a replay too. Our press release from earlier today has the specifics on accessing that replay. With us today are Liam Kelly, our Chairman, President, and Chief Executive Officer, along with Thomas Powell, Executive Vice President and Chief Financial Officer. Liam and Tom will each give prepared comments, after which we'll move to Q&A. Prior to starting, I want to note that certain topics we'll cover on this call include forward-looking statements about future events, as described in our slide. We caution that these statements are indeed forward-looking and carry risks and uncertainties, so actual events or results could differ materially. Factors that might lead actual results or events to differ materially include, without limitation, those mentioned in today's press release and in our SEC filings, such as our Form 10-K, accessible via our website. On this call, management will also discuss intra-quarter business performance. This commentary is meant to give the investment community extra perspective on trends, and these disclosures might not be repeated in later quarters. Having said that, I'll hand things over to Liam now.
Liam Kelly
executiveThanks, Larry, and good morning to all of you; I'm glad to be here with you today. Teleflex posted revenues of $704.5 million in the second quarter, which represents a 1.3% drop compared with the prior year on a reported basis and a 2.3% gain in constant currency terms. Adjusted earnings per share came in at $3.39, up 1.2% from the same period a year ago. Looking back at the quarter, execution was solid across the great majority of Teleflex, with close to 90% of the combined business generating constant currency revenue that beat the plan. As COVID hospital admissions have come down from the peaks seen earlier in the year, volumes have kept recovering in the US, EMEA, and Latin America. Even so, revenue fell short of what we had expected, since UroLift sales failed to bounce back to the levels we had projected. Leaving UroLift aside, constant currency growth for the quarter reached 4% compared with a year earlier, as the rest of the business as a whole surpassed our forecast for the period, though there were some gains and some setbacks across the portfolio as we worked through a dynamic environment. Beyond that, once you factor in the respiratory divestiture along with UroLift, what's left of the business posted a constant currency increase of 5.2%. A result like that highlights the benefits of a portfolio built with intention across many different areas, one whose primary focus is treating patients who are critically ill. In the quarter, momentum continued across most growth drivers for our high-growth portfolio, which consists of UroLift, MANTA, hemostatic products, EZ-IO, OnControl, and QuikClot. UroLift was down 13% year over year in Q2, but the remaining products in that high-growth portfolio grew more than 20%. Although the second quarter presented additional challenges, our confidence remains that the landscape will steadily improve over time—this includes for procedures that are the most elective in nature, like UroLift. In addition, we intend to continue executing the plan we presented during May's Analyst and Investor Day. Strong execution and financing our existing growth drivers remain our priorities. We will seek to expand geographically, paying particular attention to Asia Pacific. Margin expansion continues to be an opportunity as we improve the mix within our high-growth portfolio and realize cost savings. We remain prudent stewards of capital, putting internal investments first so as to speed up our innovation engine and M&A. Our corporate development group has a full pipeline of potential scale acquisitions, late-stage technology, and tuck-ins. In our view, conditions externally for transactions are improving, and our balance sheet is strong, so we stand ready to pursue deals that meet our acquisition criteria. In fact, during Q2, we closed a tuck-in within our interventional business, and we wrapped up a distributor-to-direct conversion in the early part of Q3. Although neither deal moves the needle for Teleflex in 2022, our commitment to carrying out our M&A strategy remains. Finally, we will continue advancing our CSR and DE&I efforts. Before we go further, I want to direct everyone to the 2021 Global Impact Report we'll be releasing shortly, since it highlights how far we've come with our corporate social responsibility efforts. Turning now to our second-quarter revenue results, I'll begin by reviewing performance for each of our reportable segments in Q2. All growth rates I cite reflect constant currency unless I note otherwise. Within the Americas, revenue totaled $412.7 million, down 0.3% from the prior-year period, which itself had posted growth of almost 32%; at the same time, the quarter showed improved growth trends on both a two-year and a three-year basis. Surgical was the biggest driver of growth, though declines in Interventional neurology partially offset that. In the Americas, the respiratory divestiture ended up being only a slight drag on growth for the quarter. For EMEA, we brought in $145.2 million, which represents a 3.4% increase compared with the same period last year. It was a quarter where growth came from many areas, since anesthesia, surgical, and interventional products each added meaningfully. Procedure volumes, as we've seen before, improved versus a year ago as nations across the region continued past COVID-related restrictions. Taking out the effect of the surgery divestiture, revenue was up 6.7% from a year earlier. Turning now to Asia, where revenue came to $76.6 million, an increase of 1.8% year-over-year. Korea and Southeast Asia both delivered strong results this quarter. In China, growth went negative compared with last year, which reflected the impact of COVID lockdowns during May and June. If you set aside what the surgery divestiture contributed, our Asia sales for the second quarter were up 7.3% compared with the same period a year earlier. Now I'll walk through how each global product category performed on revenues in the second quarter. Just as I noted before regarding our reportable segments, when we talk about second quarter growth for global product categories, those figures are likewise given on a constant currency basis, and we'll go through them in order from our largest business unit to the smallest. Beginning with vascular access, revenue came in at $163.9 million, which works out to a 1% increase. This quarter's results reflect in part that we saw fewer COVID intensive care unit patients than a year ago, along with fewer intensive care unit visits overall. As we look forward, the leading position we hold in our category for central venous catheters and midlines, combined with our innovative coated PICC portfolio, keeps us well positioned for growth that lasts. Looking at how we did in the second quarter, we're keeping our outlook for PICC unchanged — still expecting growth in the double digits for 2022, since we're putting investment behind our differentiated portfolio. Now turning to interventional. We brought in $114.4 million in revenue, which is 5.3% higher than a year earlier, and that came up against a difficult comparison, since the second quarter of last year saw 31% growth; given the industry headwinds from the contrast shortage, we're happy with how we performed. As far as Teleflex is concerned, the contrast shortage didn't really affect us, and things keep getting better in our view. We're still positioned to deliver constant currency growth in the high single-digit to low double-digit range for our interventional business in 2022. When it comes to MANTA, our large bore closure device, we're looking at roughly 50% growth for the full year. Moving on to anesthesia. Sales reached $104.7 million, a 14.4% increase versus the prior year, even with a tough comparison to last year. Among our bigger franchises, hemostatic products, atomization, and LMA reusable masks each added to second-quarter growth, while reduced tracheostomy product sales partly offset that. Our hemostatic products brought in more revenue than the previous quarter and exceeded our expectations for the period. In the surgical segment, we recorded $99.6 million, reflecting 5.9% growth over the same quarter last year, on top of a 39% constant currency comp the year before. Among our largest product categories, instruments fueled the gain this quarter. Even against tough year-over-year comparables and China's COVID lockdowns during the quarter, ligation kits for metal and polymer kept expanding. Now for interventional urology: sales came in at $79.8 million, a 6.9% sequential gain, but that's a 13.2% decline from the same period last year and below our own internal forecast. The better operating conditions we'd been expecting for interventional urology never materialized in Q2. April landed somewhat softer than our plan. May brought a degree of stabilization, but COVID-19's effects canceled that out, and by the time the quarter wrapped up, June turned out weaker than anticipated and well short of what we'd projected. When we look at how UroLift revenue broke down, every location where the procedure is performed saw a drop compared with the same quarter a year earlier — hospitals, ASCs, and physician offices alike. A number of things came together to shape that quarterly revenue outcome. Chief among them: the widespread recovery in urology procedure volumes that our guidance had assumed simply did not materialize.
Liam Kelly
executiveFor those of you who track Teleflex carefully, you're aware that urology procedure volumes in 2021 were still below their 2019 levels. We had anticipated that as we moved through 2022, urology practice visits would improve relative to the prior year. However, what actually occurred was a drop in patient traffic to urology in Q2, which put pressure on UroLift procedures. Beyond that, while BPH remained one of the top four disease states treated by urologists, more acute conditions requiring immediate attention — kidney stones, hematuria, and prostate cancer — continued to take precedence. A second factor: COVID-related interruptions continued to constrain UroLift procedures, including procedure cancellations in late May and persistent staffing shortages. In Q2, we conducted a survey in-house, and just over 100 urologists replied. Over half of the people who answered indicated they didn't have enough staff. Number three, in June, we started a voluntary recall for specific lots we'd identified of the UL400 UroLift System — that's the UL1 device, our first generation. It didn't matter financially to Teleflex, but it did create some interruption for the UroLift sales team in Q2 while they were handling the recall work. The UroLift problem came to light through our internal quality monitoring, which raised the possibility that once implanted and deployed, these affected devices might not deliver an implant correctly. During the procedure itself, the physician immediately spots the problem, and it interferes with getting the implant placed. After a UroLift implant has been correctly deployed and tensioned, nothing about it is affected. As part of our root cause work, we identified a production tool that fell outside specifications, located on a single line at a single site; beyond that one issue, we continue manufacturing the UL400 device. Our stock of unaffected products is sufficient, so we anticipate no difficulty supplying replacement units to customers impacted by the recall, nor in meeting upcoming customer demand. Just to confirm, there hasn't been a material effect on our consolidated financial results or operations from the recall, and we don't anticipate one. One key point: because it's made through a different manufacturing process, the UroLift 2 System isn't part of the recall. OEM revenues came in at $70 million, up 17.6% from a year earlier, driven by strong double-digit growth in every product category. Customers see the breadth of our competencies and our competitive capabilities across the markets we serve, so our order book is in a good position. I want to stress that HPC has been a terrific addition to the business since we acquired it. We've finished bringing the businesses together, and we're now competing in sectors expanding quickly — thin wall interventional micro catheters used to reach small vessels, plus fine wire serving sensing and ablating applications. Then there's our remaining group, covering respiratory product sales that weren't part of what went to Medline, urology care, and the manufacturing and supply transition agreement income tied to the respiratory divestiture. Other revenues for the second quarter came in at $72.1 million, down 10.9% compared with the same period a year earlier. That decline stems from revenue we no longer receive after selling off the respiratory products, partly offset by money coming from the manufacturing and supply transition agreement; we still anticipate that all MSA revenue streams will come to an end by the conclusion of 2023. That wraps up what I have to say regarding second quarter revenue performance. Moving on to a few commercial and clinical updates, beginning with UroLift. When it comes to our market development goal for UroLift, the quarter brought progress we were happy with; feedback from surgeons continues to be outstanding concerning the UroLift 2 along with the UroLift Advanced Tissue Control for treating obstructive median lobe. Our view is that rolling out the UroLift 2 and the Advanced Tissue Control will let us deepen our engagement with surgeons and push utilization further within our labeled indications. To be sure, in the second quarter, accounts that moved over to UroLift 2 showed greater procedure growth compared with those yet to make that change. Based on our position when the second quarter ended, we are confident in our ability to transition the great majority of U.S. customers to UroLift 2 prior to the conclusion of 2022. So, after the whole U.S. customer base has converted, we expect interventional urology margins to expand by 400 basis points as a result of the UroLift 2 transition. On top of that, during the first half of 2022, patient reception of our direct-to-consumer initiative has outperformed what we had planned. We were also gratified by our new surgeon training efforts in that same half-year period. Something worth highlighting: during Q2, we hosted our first BPH summit since the pandemic began, and over 80 physicians attended in person. Given how positive the response was, a second BPH summit is scheduled for the back half of 2022. On the clinical side, UroLift keeps distinguishing itself among outpatient BPH options, backed by solid clinical data, research showing fast symptom relief and recovery, an absence of new persistent sexual dysfunction, and lasting durability. Based on our review of clinical evidence presented at recent urology conferences, real-world retreatment rates appear to track closely with what was seen in the UroLift pivotal trial. Most recently, at the European Association of Urology annual meeting, we highlighted multiple studies. One notable real-world retrospective study looked at patients from 22 sites around the world, with differences in prostate size and morphology. In this retrospective review of UroLift cases, patients were first grouped according to prostate size, from under 30 CCs to over 80 CCs, and also by whether they had obstructive median lobe or lateral lobe obstructions. At 24 months, IPSS demonstrated meaningful improvement in every volume group. Now, turning to an update on how we are expanding UroLift internationally: we are just starting a multi-year, multi-geography push into international markets, and that effort ought to act as a significant growth driver in the coming years. UroLift's introduction in Japan kicked off on the first of April, and it's matching what we laid out, with results so far leaving us quite optimistic; we're still working closely with key opinion leaders, and procedure volumes keep climbing. Responses coming back from those early cases have been extremely favorable, and once more we're seeing robust reactions regarding how the UroLift loops perform. In fact, on a trip to Japan not long ago, I personally sat down with nineteen urologists, and what they told me about their first UroLift cases left me feeling highly upbeat. Even though we view 2022 as a year of building in Japan, our enthusiasm about what lies ahead for 2023 and afterward hasn't dimmed. For UroLift, Japan continues to represent a significant opportunity over the long haul, with a total addressable market of $2 billion, and we're thrilled to deliver this treatment, which offers real clinical benefit, to people dealing with BPH. Turning to our other markets outside the US. We're still on schedule to hit the UroLift commercial milestones we've projected, among them bringing UroLift to China and securing revised reimbursement in France, both in the fourth quarter. Now for a few reimbursement developments. CMS put out its proposed rule for the 2023 physician fee schedule on July 7, and it matched what we had anticipated. Under that proposal, CMS would cut the conversion factor by 4.4% for 2023, as the agency carries on with the four-year phase-in tied to the final rule from 2022.
Liam Kelly
executiveWe're going to keep working to engage CMS, together with a wide range of stakeholders, to make sure our physicians understand that reimbursement reductions affecting more than 600 routine office-based procedures will push care toward more expensive sites of service and reduce choices available to seniors across the United States. CMS also put out its proposed rule for the 2023 outpatient prospective payment system, which came out on July 15. Under that proposal, the facility fee would rise by an average of 2% for the ASC and 3% for the hospital outpatient setting; these rules remain open for public comment until September 2022 and won't take effect until 2023. Given the proposed modifications to the 2023 physician fee schedule and OPPS, UroLift remains the most profitable minimally invasive BPH treatment that doesn't call for an overnight hospital stay. Now moving to our interventional business. In June we announced the MANTA Ultra Study. That study, which should enroll as many as 150 patients across 15 investigational sites, aims to show the safety of MANTA ultrasound-guided closure without relying on pre-procedural depth location measurements. As we said in the press release announcing the study, access site complications are known to be tied to greater morbidity and mortality rates as well as higher costs stemming from longer lengths of stay. We also obtained Health Canada approval for MANTA in May, which will help us keep building momentum globally for our large bore closure device. That wraps up my prepared remarks. Now I'd like to hand the call over to Tom for a closer look at our second quarter financial results. Tom?
Thomas Powell
executiveThanks, Liam, and good morning. With the earlier review of how the company performed on revenue behind us, I'll start with margin. Adjusted Gross Margin came to 59.6% for the quarter, which represents a decline of 30 basis points from the same period a year earlier. That year-over-year drop stemmed from volume and mix as well as added inflation in freight, raw materials, and labor, which favorable pricing partly offset. Notably, our pricing approach kept building momentum throughout the second quarter. In the second quarter, Adjusted operating margin stood at 27.5%. The 70 basis point fall versus the prior year came about because of the lower gross margin, reduced leverage across our expense base, and planned investment in the business tied to our growth driver. Net interest expense came to $11.2 million for the second quarter, down from $15.9 million in the comparable period last year. This year-over-year reduction in net interest expense mirrors savings achieved through early redemption of the 2025-year notes along with the effect of cutting outstanding debt by using proceeds from the respiratory divestiture and operating cash flows. Our Adjusted Tax Rate for the second quarter of 2022 was 12%, versus 14.4% in the same period a year ago. The year-over-year decline in Adjusted Tax Rate stems mainly from additional enhancements in tax efficiencies within our global structure, partly offset by tax expense tied to the new provision of the U.S. tax law that requires capitalization of certain R&D expenses. At the bottom line, adjusted earnings per share for the second quarter was $3.39, which is a rise of 1.2% compared with the prior year. Normalizing for foreign exchange, incremental inflation, and the respiratory divestiture suggests underlying Adjusted EPS growth in the low double-digit range year-over-year. Now to select balance sheet and cash flow highlights. Cash flow from operations during the first half was $101.9 million, versus $265.1 million in the same period a year earlier. That decline came mainly from higher tax payments and unfavorable changes in working capital, caused by higher payable and benefit-related payments. A further factor affecting cash flow was a rise in our inventory level, intended to support future growth and to minimize the potential impact from the supply chain disruption. Now to the balance sheet. Our financial position remains healthy. At the close of the second quarter, our cash balance stood at $208.1 million, compared with $445.1 million at the end of 2021. The reduction in cash on hand results from a $135.5 million payment made in the second quarter to reduce our revolver borrowing. Following that debt payment, floating rate debt now makes up 42% of the total debt outstanding. Net leverage at quarter end was roughly 1.8 x, which remains well below our 4.5 x covenant; now turning to our 2022 guidance. We are lowering our 2022 constant currency revenue growth guidance to 3.25%-4.25% from 4%-5.5% previously. The revised constant currency revenue range amounts to a $21 million-$35 million reduction compared with our prior range, or $28 million at the midpoint. This accounts for a reduction in our outlook for UroLift revenue, partly offset by strength in the remaining businesses. If you factor in the respiratory divestiture's effect and adjust for having one fewer shipping day, then looking at the midpoint of the constant currency revenue growth guidance we issued for 2022, the business's underlying growth projection still comes in above 5% compared to last year. Turning to foreign exchange: throughout the second quarter the dollar strengthened considerably, and that includes the euro rate, which is where our exposure is greatest. In our annual guidance for 2022, we had assumed a dollar-to-euro rate of 1.12 across the year. Under our guidance now, we assume the euro averages 1.05 for the whole of 2022, and reaches parity during the second half. Our guidance now further assumes that other currency rates have been revised so they mirror today's rate environment. These updated foreign exchange assumptions add another $55 million of headwind to reported revenue; across the year, foreign exchange is now expected to drag revenue by roughly 3.7%, or $100 million, where previously the figures were 1.7% and $45 million. For 2022, we now anticipate reported revenue growth between -0.45% and +0.55%, which translates into a dollar range of $2.797 billion to $2.825 billion. Let me move on now to what we expect for UroLift. In light of the first half result and our expectation that revenue will rise sequentially during the second half, we now assume 2022 UroLift revenue will decline modestly versus last year, landing at approximately $335 million, compared with earlier guidance calling for 15% growth. This updated assumption means a $58 million cut to UroLift revenue relative to what our earlier guidance range had built in. As we look toward the second half of 2022, we anticipate a better environment for UroLift provided the macro backdrop improves, utilization rises, and new exchange surgeons get up to speed. Worth noting: our present UroLift revenue outlook for 2022 builds in growth during the second half, with revenue climbing sequentially in the third quarter and climbing again sequentially in the fourth quarter. We have made no changes to the assumptions behind the international UroLift outlook, since our rollout in Japan, initial launch in China, and reimbursement update in France all remain on track. Now to the middle of the income statement. For 2022, we expect gross margin of 59%-59.5%. Freight and labor inflation are still broadly consistent with what we expected, but raw material costs are coming in above earlier projections. As a result, we now project an inflation headwind of 100 basis points for 2022, up from 70 basis points before. Keep in mind this sits on top of the inflation we normally experience in any given year. Our outlook reflects how we see the rest of the year and assumes no meaningful easing in overall material inflation. Importantly, price continues to offset inflation, and we are confident we can deliver at least 50 basis points of price this year. As a matter of course, we will keep evaluating our global pricing and make adjustments whenever opportunities appear. When it comes to operating margin, our expectation now is that it will land somewhere between 26.75% and 27.25%. This guidance takes into account the growth margin we foresee along with reduced leverage throughout our operating expense base. Moving on to earnings, we're lowering the adjusted earnings per share guidance for 2022 to $13-$13.40, down from the earlier range of $13.70-$14.30. That works out to a 2.5% decrease at the low end and a 0.5-point rise compared to last year at the high end. In terms of bridging from our prior Adjusted EPS guidance, there's a $0.60 reduction tied to our updated outlook for UroLift. Foreign exchange has become a $0.46 headwind, compared to the $0.20 we assumed before. Additional inflation now represents a $0.47 headwind, up from $0.33 earlier, because of higher raw material costs. These extra headwinds are partly offset by a better operational outlook in other parts of our business. As it stands, our guidance incorporates a $0.15 headwind from the respiratory divestiture. If we normalize for the additional inflation, foreign exchange, and the respiratory divestiture, that points to underlying Adjusted EPS growth at the midpoint of guidance in the high single-digit range compared to last year for 2022, and it shows the advantages of our varied product lineup and our capacity to increase earnings during a time of considerable macroeconomic difficulty. That wraps up my prepared remarks. I'll hand it back to Liam now for closing comments.
Liam Kelly
executiveThanks, Tom. To wrap up, I want to go over three main points regarding Q2 and what we expect for 2022. To begin with, because our product lineup is diversified, Teleflex achieved constant currency growth of 2.3% during the second quarter, even with significant macroeconomic headwinds. And if you set aside the drag caused by the respiratory divestiture, growth in the underlying business came to 3.5%. Next, we'll keep running the business efficiently and seek opportunities to reduce added pressure from inflation and difficulties in the supply chain. Although recent UroLift revenue figures are underwhelming, the outlook we've provided suggests a better growth path during the back half of the year. On top of that, we're in a strong position for when the macro pressures on the urology market ease. Finally, we're still carrying out our long-term growth plan. We'll keep investing incrementally in our high-growth portfolio while generating steady expansion in our durable core portfolio. We have the mechanisms in place to push margins higher, and with leverage at 1.8 x, our balance sheet remains strong, giving us plenty of financial flexibility for our capital allocation priorities, such as mergers and acquisitions. That's everything I had prepared. At this point, I'd like to hand the call back to the operator so we can begin Q&A.
Cecilia Furlong
analystThanks. Morning, and I appreciate you taking my questions. Liam, I'd like to begin with UroLift and really just get some additional detail on how you're viewing the back half, the updated guidance, whether that includes contributions from backlog returning, whether it's ramping volumes among your previous high volume utilizers, DTC, just some sense of the mix and how you're weighing the environment. Also, really, your longer-term perspective on that 15% growth for the business overall, and how you're considering possible backlog recapture in 2022 and past that.
Liam Kelly
executiveAll right, Cecilia. Let's begin with the full-year outlook for UroLift. Clearly, our earlier guidance presumed 15% growth, which would have meant revenue of $393 million. Because of the present market conditions that I discussed during my prepared remarks, we now anticipate $335 million, which represents a decrease of $58 million, or roughly 2% for Teleflex as a whole. Before I go into the components of UroLift, I want to note that our constant currency call down at the midpoint is 1%, which signals that the remainder of the portfolio is beating expectations by about $30 million. I'd note that a substantial share of that outperformance is coming from the high growth, high-margin portfolios like hemostats, intraosseous and PICCs and similar products. To answer your question, the revised UroLift guidance does not build in any meaningful betterment in the operating environment. Basically, we're taking our quarter two revenue run rate and assuming sequential improvement into Q3 and additional sequential improvement into Q4. That would clearly suggest positive growth in the back half of 2022. I also want to note that the revised guidance for UroLift rests on slower urology procedural recovery trends in the U.S. Our assumptions for OUS remain unchanged on that front. As for the backlog, we are not assuming any backlog will return in the latter half of the year. I think what we've observed is that the UroLift procedure remains a very postponable procedure, and patients are still reluctant to return to the urologists. There's also a staffing shortage, as I discussed during my prepared remarks. That's what we're assuming in the back half, Cecilia, for UroLift and an update on the call down for the full year.
Jayson Bedford
analystMorning. Am I coming through fine?
Liam Kelly
executiveYes, Jayson, you're coming through. Thanks.
Jayson Bedford
analystPerhaps a quick follow-up regarding UroLift. From what I recall, you noted in the script that improved utilization is being seen among those accounts utilizing UL2. There are, you know, numerous explanations for this, but I'm curious about which initiatives you've implemented to potentially speed up the shift to UL2?
Liam Kelly
executiveJayson, the pace of conversion we're currently observing makes us quite happy. In fact, we're a bit ahead of our plan — the internal one we set out at the year's start. What we're observing is that as surgeons transition to the UL2, it gives us a chance to bring in the advanced tissue control, and those two new products together are in fact generating higher throughput in those practices. It comes from the sales force re-engaging with the surgeon, and it also comes from broadening the size and complexity of prostates that the surgeon is prepared to treat, since the outcomes with the UL2 are in fact superior to the UL1, and clearly, they feel far more at ease performing median lobes with the advanced tissue control. We're ahead of our plan, and we do expect to have the bulk of the North American, the US market converted by the end of this year. That will also lead, clearly, to that 400 basis points in margin expansion for the UroLift product.
Jayson Bedford
analystAll right. Generally speaking, Liam, during the past six months, has anything about the UroLift approach shifted? What I mean is, you introduced a fresh approach when the year started. Clearly, things have moved somewhat slower. Has there been any adjustment to that approach?
Liam Kelly
executiveThe approach remains unchanged, since it's delivering results, in that we observed improvement from Q1 into Q2 on a sequential basis. In fact, UroLift posted 7% growth quarter-over-quarter. We must keep in mind that they faced a very difficult comparison in the year before. During that prior year, it climbed more than 120%. It fell short of what we expected, but regarding physicians, what we observe is that the newly trained doctors are the ones involved, and among those newly trained docs, we're seeing cases per physician get better; we also added a greater number of high-volume physicians in quarter two. So that's the reason we feel encouraged about Q3 showing sequential improvement, plus Q4 delivering even more sequential improvement, Jayson.
Matthew O'Brien
analystGood morning, and thank you for taking my questions. I'd like to pick up where the UroLift discussion left off, and I'll get those questions out right away. Liam, if we're looking at a decline of roughly $60 million for UroLift this year, how much of that comes from the volume effect you're seeing among patients visiting urologists, as opposed to perhaps losing some people due to the recall or competitive launches, or reimbursement headwinds? And to sharpen the second question a bit, are you still able to grow UroLift 15% in 2023, 2024, and 2025, as you said at the Analyst Day? Thank you.
Liam Kelly
executiveAll right. Matt, there are several factors wrapped up in that question. Based on what we can see, reimbursement is not a driver here. We can also say with confidence that competitive dynamics are not playing a role. As for the recall, its impact was relatively minor. There was some modest disruption to our sales force, since we needed to swap out product for the customer, get new product in place, and secure the comp — so that created some interruption. Let me put it this way: looking at UroLift's results for the year, what we're seeing is that patient throughput and in-person visits to urologists declined in Q2 relative to the same quarter last year, and that compounds the decline we saw in 2021 versus 2019. On top of that, staffing shortages are creating additional headwinds for us. We did an internal survey with over 100 urologists, and a majority—more than half—mentioned that their practices are dealing with staffing shortages. That issue keeps compounding. Our strong view is that what's driving the volatility out there is end market conditions. Like I mentioned to Cecilia, what we're seeing is that this procedure is highly deferrable. If your BPH isn't treated, it won't kill you. Then, on the longer-term side and your LRP question, let me make sure everyone's on the same page: the LRP had Teleflex at a 6%-7% CAGR and UroLift at a 15% CAGR. We used 2022 as the jump off, and I think that's an important point to keep in mind. My confidence in the roadmap we laid out at Investor Day hasn't changed. Taking UroLift out along with the respiratory divestiture, our durable core expanded 4% during Q2. When you examine Q2 without UroLift, the growth we actually posted picked up speed. And once more, setting aside the respiratory divestiture, we moved from 4.5% in Q1 up to 5.2% in Q2. The remaining 90% of the business is doing really well. Yes, UroLift did fall in Q2, but at Teleflex I believe our position is strong for whenever the BPH market turns around. Our sales force is at full strength and ready for that recovery. This market remains enormous. The US portion alone is $6 billion, with another $6 billion coming from overseas. Our technology for minimally invasive treatment leads the market, delivers results right away, avoids any sexual dysfunction, and means patients don't have to use a catheter. During my prepared remarks, I noted that we expect improvements from one quarter to the next in Q3, followed by yet another sequential increase in Q4, which clearly backs up the run rate we're carrying into 2023. While we haven't changed our guidance for this year in markets outside the U.S., we're still growing internationally. Japan is doing very well. We should start seeing contributions from China and France in Q4. Reimbursement in France is expected to be secured in Q4. In Italy and Spain, we continue seeding those markets one region at a time. During 2023 and 2024, Germany, Taiwan, and India will come into view, and Brazil reimbursement should arrive near the end of 2024. That's the reason I have confidence in the overall LRP we presented, and clearly in the UroLift CAGR within that LRP.
Shagun Singh
analystThanks a lot for fielding the questions. Liam, Tom, I realize it's still early days, but might you share some additional perspective past 2022? UroLift has served as a key engine of growth for your company. That's a component of the thesis that carries you toward your 6%-7% goal. So, how worried are you about an economic downturn and what it might do to that business? And how do you view M&A as a way to further accelerate or perhaps even sustain this growth path over a longer horizon? If I could squeeze in one more about the macro items, FX and inflation, what assumptions have you made, what effect does that have on EPS, in 2022, and how much carries over into 2023? Thanks for fielding the questions.
Liam Kelly
executiveAll right. I'll have Tom address the FX and inflation piece. I'll handle the couple of macro questions. When it comes to the possibility of entering a recession, my view is that Teleflex is well positioned. No industry escapes a recession and its effects, but my sense is that medical devices broadly have been shielded from what a recession does. And I believe Teleflex specifically will be shielded even more than other kinds of medical device companies. The basis for that claim is that at Teleflex, our entire portfolio leans toward the older population. Typically, when you head into one, if you examine the prior recession, and if you examine jobless figures, and the reason I bring up jobless figures is that they affect insurance coverage for those people. If you examine the prior recession, joblessness climbed to roughly 11%. If you examine the demographics, for those above the age of 55, joblessness stood at roughly 7%, and it was twice that for those below the age of 55. Since our portfolio leans toward that group, I believe we would be, to some degree, not entirely insulated, but to some degree shielded, from a recession. As for that question specifically about UroLift, with 12 million men in the United States suffering from BPH and 100 million globally, there's a sufficient patient population there to keep growing UroLift even in that kind of environment. As for your question about M&A in the current environment, clearly interest rates have risen, so, the cost of funding has gone up. Still, I do believe that the environment is more welcoming to more sensible valuations right now than it has been at any point in the past. As I mentioned in my prepared remarks, we are out there actively right now. We feel good about the environment. Our leverage sits at 1.8 x, so we have firepower. We are pursuing assets at the moment. We are evaluating scale transactions, tuck-in transactions. As you heard in my prepared remarks, we announced a late-stage technology in a distributor-to-direct. Not that material for Teleflex, but even so a sign that we're active out there in the market evaluating M&A in this current environment. If it's alright with you, I'll hand the questions about FX and inflation over to Tom, Tom.
Thomas Powell
executiveSure. Starting with currency effects, the hit to this year's revenue is now about $100 million. Earlier, we were looking at $45 million. That adds another $55 million, based on where exchange rates stand this week. Where earnings are concerned from FX, the full-year figure has risen to $0.46, compared with $0.20 before. Turning to next year, I clearly can't predict currency levels for early next year. If they stay where they are right now, we'd face a modest additional impact, since both the first quarter and the second quarter were stronger than today's rates. Again, only time will tell how currencies move next year before I can answer that. On added inflation, we now anticipate $0.47 hitting earnings, up from $0.33 earlier. That's mostly because raw material costs keep climbing, though we are in fact seeing some steadiness in certain logistics and sea freight areas. That's a promising signal.
Matthew Mishan
analystOh, that's great — I appreciate you taking my questions. I've got a couple, and just to mix things up a bit, they're on UroLift. To start, what exactly rebounds within interventional during the back half to bring you to double-digit — or high single-digit, double-digit — growth across the year?
Liam Kelly
executiveRegarding interventional, you've got it right; the second half does accelerate. Clearly, MANTA is among the things driving that. Like we mentioned, we're looking for MANTA to expand at roughly the 50% level, and it will account for a meaningful share of that growth; beyond that, certain products of ours faced some supply chain interruption during Q2, and that clears up over the back half. Also coming back to the market in that same period is the Langston product, and that's what fuels the acceleration. A bit of favorable year-over-year comparison contributes too, Matt, yet we have confidence that from a revenue standpoint, interventional access reaches high single digits, low double digits over the back half of the year.
Matthew Mishan
analystAll right. Great. Regarding free cash flow, Tom, you went through a few of the shifting components from the first half, and I believe higher working capital has been a topic for everyone. So, when you consider the entire year, what should our approach be to full-year free cash flow projections at this stage?
Thomas Powell
executiveSure. For the whole year at present, operating cash flow falls within $400-$450, while CapEx lands between $75 million-$80 million. A number of the factors that hit the first quarter and first half are going to carry through the entire year regarding, you know, the reason it's not matching last year's strength. A one-time tax outlay in this year that gets recovered across the following two years is fairly substantial; plus there are shifts in working capital, where, you know, we've built up inventories to ensure we have enough supply as a cushion against supply chain interruptions; we also enjoyed a very robust AR collection last year, which we don't anticipate happening again in this year.
Liam Kelly
executiveThat happened right at the close of last year, and we don't anticipate it happening again. Venice also pointed to higher compensation tied to payroll. The payouts in early 2021 were just lower because of how 2020 performed, you know. Now we're back to a typical payout level for this year; those are among the main reasons why cash flow this year isn't as strong as it used to be.
Mike Polark
analystHi there, good morning, and thanks for taking my questions. I have two short follow-ups on UroLift, and then one broader question, if that's alright. On the recall, was everything wrapped up by the end of June, or does some of it spill into July and August? And with July underway, would you be willing to venture any comment on UroLift volumes so far this month? Then the wider question: you mentioned once or twice that certain pricing actions are already delivering favorable benefits. Could you remind us, broadly across the portfolio, what exactly you're doing on that front? Give us a sense of magnitude — what sort of benefit are you pursuing, and over what kind of timeframe might those benefits begin showing up in the numbers? Thanks so much for taking the questions.
Liam Kelly
executiveAlright. Let me begin with pricing. When we set out our plan, pricing was going to contribute 50 basis points. For the year, we'll be at 50 basis points at minimum. As I sit here today, we're running ahead of that target. The places where we apply price increases: our surgical business is performing well, our vascular business has been doing well, and our anesthesia business has also been generating some of that pricing. On the recall, yes, it's completely behind us for the quarter. We booked all of the reserves for the inventory. Those were taken back in quarter two, and our financial results already reflect all of it. As for your question about UroLift growth ahead in the quarter and what's going on in July, I'd rather not get into July specifically, but what I said earlier covers it. We anticipate sequential improvement in Q3, followed by additional sequential improvement in Q4. That's the indication we have at this point.
Craig Bijou
analystThanks, everyone, for fielding the questions. I've got one about your list, plus a follow-up regarding margins. At the Analyst Day at the end of May, you all still appeared quite confident. Sorry for such a granular question. Liam, I'm aware you gave a bit of detail about the monthly performance. So, how did June compare sequentially with May? It looks like if you all felt quite strong at the Analyst Day, and then, well, there's a fairly sizable miss here. I realize you didn't receive the revenue you expected in June from UroLift. I was hoping that maybe we could get a little understanding about the sequential growth during the quarter, if you're willing. Absolutely — first, to set the baseline, we came in roughly $14 million below where we needed to be for the quarter. At the beginning of the year, when guidance was issued — and you're right that we restated it during quarter two at Analyst Day — our expectation was that conditions would strengthen from April through June. April landed a bit below what we had planned. Then May did improve, even with COVID cancellations happening that month; however, the lift we were looking for in June never materialized. Honestly, June was a rough month for UroLift. In fact, June performed worse than both of the prior two months and lost momentum. The recall did have some effect—mainly on when sales happened. But I'd say the bigger drivers were the things I already mentioned: fewer in-person urologist visits compared with a year earlier, plus urology offices being short-staffed, which limits how many patients they can get through. In our survey of urologists—conducted during the quarter, so it captured that COVID period—they all cited what they called "cancellations from patients due to COVID," whether because the patient was infected or because they'd had close contact. That's a reasonable question, and June was definitely worse than the other two months.
Craig Bijou
analystExcellent. Thank you, Liam. So when it comes to margins, specifically for 2023 or beyond — and I realize you won't be giving guidance — but considering a few of the headwinds that are pushing margins lower in the current year, along with the smaller absolute level of UroLift revenue this year, how are we to think about your capacity to grow margins as we look toward 2023?
Liam Kelly
executiveTom, would you mind addressing that one?
Thomas Powell
executiveFrom a big-picture standpoint, as we look ahead, a few factors are going to shape future margins. One of them is clearly product mix—and we've discussed both our high-growth product portfolio and our higher-margin offerings. As those keep expanding, they'll deliver a solid mix advantage, since they account for a disproportionate share of the company's growth; and of course, with UroLift, we've got to get it back on track and expanding so we can hit everything we set out to achieve in the Analyst Day guidance. Beyond that, looking at other drivers, we have restructuring programs in place that, based on what's been announced and what's currently active, still have roughly $45 million in savings to be captured. On top of that, there are numerous cost improvement efforts happening annually across the plants, distribution centers, and so forth, which generate significant productivity gains. A great deal of that is Six Sigma-style work. Those are the primary drivers for us. When we think about the guidance we gave at the Analyst Day, we had assumed an inflationary environment would persist across the entire LRP timeframe, though not quite at this year's level. We had built in the assumption that inflationary pressures would continue, and that remains our view today given what we're observing.
Richard Newitter
analystHello, and thank you for allowing me to ask. Let me return to UroLift briefly. I'm wondering whether I fully grasp that the main factor is the broader backdrop — office visits still aren't at the level you require, there are staffing shortages, and perhaps some recall effect. Yet is there anything additional your teams are observing out in the field regarding possible movement of share toward other minimally invasive options or even procedures that are more invasive? Is anything like that occurring, and what about retreatment rates and any shift in how physicians perceive even the more conventional surgical methods? Thank you.
Liam Kelly
executiveYes. To begin with the treatment rates, the Kaplan-Meier study — a retrospective analysis covering 35,000 patients — showed plainly that revision rates for UroLift closely matched TURP and sat well beneath the revision rates of other technologies present in the marketplace. As for share shift, no, Richard, that is the straightforward and candid response; we have not detected any share shift in the marketplace. We've examined every account that does business with UroLift and Teleflex, and no share shift has appeared within our existing accounts. Our strong conviction is that end market dynamics are what is affecting UroLift, together with the postponable nature of the procedure. Yes, I believe that's. That would be my response.
Richard Newitter
analystAll right, that makes sense. Understood.
Mike Matson
analystYes, thank you. There are a couple of things I want to ask about, and I'll put them both out there. The first one concerns UroLift. Specifically, DTC. You continue to bring up those metrics and mention how they're exceeding what was expected, and so on. I suppose what I'm trying to figure out is this: we're nearly 12 months in at this point. What exactly is happening with those patients? Wouldn't the real gauge, or the metric that matters most, be procedure growth? Because that number is negative. Is it simply that these patients haven't yet booked appointments with their urologists? Or could it be that urologists are rejecting them since they're too occupied performing other procedures, or for some similar reason? My next question isn't about UroLift — it's about Vascular Access. Growth there came in slower, and you identified certain factors responsible for that. I'm curious whether that might keep going past Q2? Thanks.
Liam Kelly
executiveYes, Mike, appreciate it. On the DTC front, we're quite happy with how DTC has performed. Six months in, we're exceeding every one of our metrics concerning patients we forward to urologists via the various media channels; our survey data tells us urologists now need considerably more time to get these patients scheduled; that window has stretched out; in our view, DTC's purpose is to educate men that UroLift is available and to transition those men into a urologist's care so the procedure ultimately happens. You're right about that. Patient flow and volume ought to be the definitive gauge. Regrettably, given today's conditions, the number of patients flowing in to urologists has declined. Staffing shortages are likewise limiting urologists' capacity to perform these procedures. As for what you asked about Vascular Access: during the quarter, Vascular Access posted 1% growth. The reason was a drop in intensive care patient visits tied to COVID. This is among the businesses experiencing certain supply chain interruptions. During Q2, we've had a somewhat elevated backorder issue affecting our Vascular Access portfolio. For the full year, Mike, we continue to anticipate mid-single digits% growth.
Lawrence Keusch
executiveThanks, Darius. And I appreciate all of you for being with us on today's call. That brings the Teleflex Incorporated second quarter 2022 earnings conference call to a close.
Operator
operatorThat brings today's conference call to a close. We appreciate everyone for joining in. You're free to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.